Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer

International Journal of Urology

Volumn 8, Issue 2, 2001, Pages 33-36

  Kitamura, Tadaichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Advanced prostate cancer; Estramustine phosphate sodium (EMP); First line monotherapy

Indexed keywords

DIETHYLSTILBESTROL; ESTRADIOL; ESTRAMUSTINE PHOSPHATE SODIUM; FOLLITROPIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANTINEOPLASTIC ACTIVITY; CARDIOVASCULAR DISEASE; CYTOTOXICITY; DAIRY PRODUCT; DOSE RESPONSE; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOPHYSIS GONAD SYSTEM; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TESTOSTERONE BLOOD LEVEL;

ANTINEOPLASTIC AGENTS, HORMONAL; ESTRAMUSTINE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0035083692     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2001.00254.x     Document Type: Review

References (9)

1. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer
2. The present role of estramustine phosphate in advanced prostate cancer
3. Clinical study on the treatment of prostatic carcinoma with Estracyt
4. Nonsteroidal antiandrogen monotherapy of metastatic cancer of the prostate
5. Interaction of estramustine with microtubule associated proteins in vivo
6. Growth and cell survival following treatment with estramustine, nornitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line
7. Impairment of estramustine phosphate absorption by concomitant intake of milk and food
8. Hormonal effects of different doses of estramustine phosphate (Estracyt) in patients with prostatic carcinoma
9. Estramustine phosphate in prostate cancer. EORTC experience: Preliminary results of Protocol 30762